Biotech Values

[dewophile]

I wonder if Amgen is interested to try a CD47 + CD3 combo, TTI621 + Blincyto in ALL

i don't think ALL is even one of the cohorts in the expansion trial. I think future combos are going to be driven by preclinical data like the recent multiple myeloma abstract, or in indications that show some activity already like perhaps AML. the platelet issue for AML is tricky - you can't just add most chemo, but the cd33 directed drug that amgen has might pair well and be a creative alternative path to market compared to say the SGEN cd33 drug which is farther along than AMGN